Nilotinib

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

CML in Chronic Phase

Conditions

CML in Chronic Phase

Trial Timeline

May 1, 2010 → Jul 1, 2014

NCT ID

NCT01061177

About Nilotinib

Nilotinib is a approved stage product being developed by Novartis for CML in Chronic Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT01061177. Target conditions include CML in Chronic Phase.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04559555	Pre-clinical	Completed	—	—	Acute Lymphoblastic Leukemia (ALL)
NCT04498871	Pre-clinical	Completed	—	—	Hypereosinophilic Syndrome (HES)
NCT04518644	Pre-clinical	Completed	—	—	Chronic Myelogenous Leukemia (CML)
NCT02774512	Phase 1	Withdrawn	May 1, 2016	Nov 1, 2017	Colon Cancer
NCT02546674	Approved	Completed	Feb 18, 2016	Mar 25, 2021	Chronic Myeloid Leukemia
NCT02115386	Phase 3	Terminated	Dec 17, 2015	Oct 31, 2016	Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
NCT02353728	Phase 2	Completed	Jan 1, 2015	Feb 1, 2021	Chronic Myeloid Leukemia
NCT02108951	Phase 3	Terminated	Jul 7, 2014	Aug 10, 2016	Philidelphia Positive Chronic Myeloid Leukaemia
NCT01844765	Phase 2	Completed	Aug 20, 2013	Aug 28, 2020	Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
NCT01744665	Phase 2	Completed	Aug 12, 2013	Sep 29, 2018	CML
NCT01863745	Phase 2	Completed	Jun 25, 2013	Oct 2, 2023	Gastrointestinal Stromal Tumors
NCT03332511	Approved	Completed	May 6, 2013	Oct 24, 2016	Chronic Myeloid Leukemia, Chronic Phase
NCT01743989	Phase 3	Completed	Apr 15, 2013	Jul 8, 2020	Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT01735955	Approved	Completed	Mar 29, 2013	Jul 7, 2023	Chronic Myelogenous Leukemia (CML)
NCT01698905	Phase 2	Completed	Dec 20, 2012	Jan 29, 2025	Chronic Myeloid Leukemia
NCT01562847	Pre-clinical	UNKNOWN	Jul 1, 2011	Jun 1, 2015	Chronic Myeloid Leukemia
NCT01077544	Phase 1	Completed	Apr 14, 2011	Jul 1, 2015	Chronic Myeloid Leukemia
NCT01254188	Phase 3	Completed	Apr 1, 2011	Nov 1, 2014	Chronic Myeloid Leukemia
NCT01274351	Phase 2	Completed	Jan 25, 2011	Aug 1, 2019	Chronic Myelogenous Leukemia
NCT01270893	Phase 2	Withdrawn	Jan 1, 2011	—	Gastrointestinal Cancer

Competing Products

20 competing products in CML in Chronic Phase

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	76
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
LY3556050 + Placebo	Eli Lilly	Phase 2	52
THB001	Third Harmonic Bio	Phase 1	25
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 1/2	33
Briquilimab	Jasper Therapeutics	Phase 2	44
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	77
LY3461767 + Placebo	Eli Lilly	Phase 1	33
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
LYR-210	Lyra Therapeutics	Phase 2	44
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	44
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	25
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	69

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved